About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Ajanta Pharma Ltd.
Change Company
BSE Code
532331
ISIN Demat
INE031B01049
Book Value
350.00
NSE Code
AJANTPHARM
Dividend Yield %
0.98
Market Cap
356360.13
P/E
37.79
EPS
75.48
Face Value
2
1 Week
1 Month
3 Months
6 Months
1 Year
05-Feb-2026
Ajanta Pharma informs about earnings call transcr...
02-Feb-2026
Ajanta Pharma informs about analyst meet
02-Feb-2026
Ajanta Pharma informs about newspaper publication
30-Jan-2026
Intimation Of Vesting And Cash Settlement Of Sto...
13-Jan-2026
Ajanta Pharma incorporates wholly owned subsidiar...
12-Jan-2026
Ajanta Pharma informs about earnings conference ...
24-Dec-2025
Ajanta Pharma enters into in-licensing agreement ...
24-Dec-2025
Ajanta Pharma shines on entering into in-licensin...
19-Dec-2025
Ajanta Pharma informs about disclosures
06-Nov-2025
Ajanta Pharma informs about transcript of earnin...
24-Oct-2025
Ajanta Pharma informs about update on board meet...
03-Oct-2025
Ajanta Pharma informs about updates
16-Sep-2025
Ajanta Pharma inform about disclosure
02-Sep-2025
Ajanta Pharma informs about analyst meet
29-Jul-2025
Ajanta Pharma informs about press release
Page
1
of
2
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.